Security key
92790C104
VIRIDIAN THERAPEUTICS INC - COMMON STOCK (VRDN)
CUSIP: 92790C104
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 110,986,695
- Total 13F value
- $2,169,454,302
- Share change
- +3,780,768
- Put/Call ratio
- 146%
- SEC-reported price per share
- $19.56
- Number of holders
- 223
- Value change
- +$31,831,601
- Number of buys
- 120
- Number of sells
- 113
- Shares outstanding
- 111,363,200
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
223
Top holders
10
VRDN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Viridian Therapeutics, Inc.\DE SEC filings
Viridian Therapeutics, Inc.\DE company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92790C104
Recent filing periods:
Ownership snapshot
Top reported holders of VRDN - VIRIDIAN THERAPEUTICS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bellevue Group AG
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
Lead comparable stake: 6.6%
13D/G row: Bellevue Group AG
Showing 1-6 of 15 holder rows.
Quick read
Bellevue Group AG leads the comparable SEC ownership view at 6.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bellevue Group AG's linked filing trail.
Comparable ownership
Top 5
Bellevue Group AG
6.6%
Venrock Healthcare Capital Partne...
4.5%
Commodore Capital LP
3.9%
Kynam Capital Management, LP
1.5%
FMR LLC
13%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bellevue Group AG |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$135,637,360
4,358,527 shares
|
— | 31 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.5%
|
$48,373,931
3,575,309 shares
|
$0 | 31 Dec 2024 |
| Commodore Capital LP |
13D/G
|
3.9%
|
$69,056,000
3,200,000 shares
|
-$23,738,000 | 30 Sep 2025 |
| Kynam Capital Management, LP |
13D/G
13F
Company
|
1.5%
|
$46,689,677
1,470,541 shares
|
+$46,689,677 | 31 Dec 2025 |
| FMR LLC |
13F
Company
|
13%
|
$447,644,271
14,384,456 shares
|
— | 31 Dec 2025 |
| BlackRock, Inc. |
13F
Company
|
5.8%
|
$200,161,442
6,431,923 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
223
Shares
110,986,695
Rows available
223
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
223
Q1 2026 holders
223
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend